Lead Toxicology and Neurodevelopmental Toxicity

Lead and Compounds (Inorganic) — Toxicology Summary

CASRN 7439-92-1 | RoseyFields Chemical-Specific Toxicology Series

RoseyFields evaluates the toxicology of lead using the following evidence base.

A note on sourcing: EPA’s IRIS chemical assessment summary for lead (CASRN 7439-92-1) is a risk-assessment document, not a toxicology review — it presents a carcinogenicity weight-of-evidence classification and summarizes several animal renal-tumor bioassays, but does not catalog toxicokinetics, mechanism of action, or organ-system-specific animal findings for lead’s noncarcinogenic effects (indeed, IRIS states no oral RfD or inhalation RfC was derived precisely because standard toxicological methods do not fit lead well). This page therefore draws on the broader peer-reviewed toxicology literature to build out ADME, mechanism, and organ system evidence, while carrying forward the animal carcinogenicity studies and human epidemiological findings actually cited in the IRIS bibliography. Every specific study, species, dose, and finding below is attributed to its original peer-reviewed source, not to the IRIS document.

1. Chemical Identity and Physicochemical Properties Relevant to Toxicity

Lead (Pb, CASRN 7439-92-1, atomic number 82) is a soft, malleable, bluish-gray post-transition metal. Toxicologically relevant assessments generally address “lead and compounds (inorganic)” — elemental lead and inorganic salts such as lead acetate, lead subacetate, lead oxide, and lead chromate — as distinct from organolead compounds (e.g., tetraethyl lead), which have different toxicokinetics and are assessed separately.

• Persistence: lead is an element and therefore does not degrade; once released to soil, dust, or water it persists indefinitely absent physical removal or immobilization.
• Bioaccumulation: lead bioaccumulates within an organism’s lifetime rather than biomagnifying substantially up food chains in the classic sense; the dominant reservoir is the skeleton, which sequesters roughly 90–95% of adult body lead burden, with a bone half-life on the order of a decade or more, compared with a blood elimination half-life of about 30 days (Rabinowitz, 1991).
• Reactivity and speciation: lead’s toxicity and bioavailability vary substantially by chemical species and solubility — soluble salts (acetate, nitrate) are far more bioavailable via ingestion than metallic lead or sparingly soluble compounds, which is why nearly all oral animal bioassays (see Section 5) use soluble lead acetate or subacetate rather than metallic lead.
• No known biological function: no essential physiological role for lead has been identified in mammals, distinguishing its toxicology from that of essential trace metals with narrow safe ranges (e.g., zinc, copper, iron), with which lead nonetheless competitively interacts.

2. Toxicokinetics (ADME)

Absorption

Lead is absorbed via ingestion, inhalation, and, to a minor extent, dermal contact. Gastrointestinal absorption is strongly age-dependent: adults absorb roughly 3–15% of ingested soluble lead when it is co-ingested with food, rising toward 40–50% during fasting, whereas children absorb a substantially higher fraction of ingested lead — on the order of 40–50% — regardless of fasting state, a difference attributed to higher intestinal permeability and

RoseyFields — Chemical-Specific Toxicology Page: Lead

higher calcium and vitamin D transport activity during rapid skeletal growth. Iron and calcium status further modulate absorption: iron-deficient children absorb proportionally more lead, and co-administered calcium reduces lead absorption in both human and animal studies. Inhaled lead in fine particulate form (as from combustion or smelting) is absorbed with high efficiency (approaching 100% for the respirable fraction) directly across the alveolar epithelium.

Distribution

Following absorption, lead enters the bloodstream, where more than 95% of circulating lead is bound to erythrocyte proteins rather than remaining in plasma. Rabinowitz, Wetherill, and Kopple (1976), using stable-isotope tracer studies in adult volunteers, established the now-standard three-compartment toxicokinetic model of lead disposition: a rapidly exchanging blood compartment, an intermediate-turnover soft-tissue compartment, and a slowly exchanging, high-capacity bone compartment that ultimately sequesters the great majority of the body’s lead burden. Because bone lead has a multi-year to multi-decade half-life, it functions as a long-term internal exposure reservoir that can be mobilized back into blood during physiological states of increased bone turnover — notably pregnancy, lactation, menopause, and osteoporosis — independent of current external exposure.

Metabolism

Lead is not metabolized or biotransformed; as an element, it is neither synthesized nor degraded by the body. Its toxicological activity instead derives from direct binding to sulfhydryl, carboxyl, and phosphate groups on structural and functional proteins, and from ionic mimicry of essential divalent cations, principally calcium and, to a lesser extent, zinc (see Section 3).

Excretion

Lead is eliminated primarily via the kidneys (urine) and, to a lesser extent, via biliary/fecal excretion, with minor additional routes including sweat, saliva, hair, nails, and breast milk. Renal clearance is relatively inefficient, contributing to lead’s long biological persistence relative to many other xenobiotics; young children have comparatively lower glomerular filtration rates and less efficient tubular handling, which may further reduce excretory efficiency relative to adults.

Species and Sex Differences Relevant to Interpreting Animal Data

• Age-dependent gastrointestinal absorption (higher in juvenile than adult animals) parallels the child-versus adult difference seen in humans, supporting the use of developmental-exposure animal models to inform pediatric risk, but requiring caution in extrapolating adult-only animal dosing to children.
• Rodent renal lead-handling differs quantitatively from that of humans and nonhuman primates; the intranuclear inclusion bodies characteristic of rat proximal tubule lead sequestration (Goyer, 1968) are a rodent-prominent finding that may over- or under-represent human renal susceptibility depending on the endpoint.
• Sex differences in lead toxicokinetics have been reported, with some studies finding higher blood lead levels in males than females at comparable exposure, which is relevant when interpreting single-sex animal bioassays (many older cancer and reproductive bioassays, including several summarized in Section 5, used only male animals).
• Nonhuman primates (e.g., Macaca fascicularis in Rice et al., 1979) are generally regarded as the most toxicokinetically comparable animal model to humans for neurobehavioral endpoints, while rodent studies, though far more numerous, require greater caution in direct extrapolation of dose-response magnitude.

3. Mechanism(s) of Action

RoseyFields — Chemical-Specific Toxicology Page: Lead

Lead’s toxicity is not mediated through a single receptor or pathway but through several convergent molecular mechanisms, each well characterized mechanistically though not always precisely quantified in dose-response terms:

Inhibition of Heme Biosynthesis

Lead’s best-characterized biochemical target is the heme synthesis pathway. Lead substitutes for the catalytic zinc ion in δ-aminolevulinic acid dehydratase (ALAD, also called porphobilinogen synthase), inactivating the enzyme and causing accumulation of its substrate, δ-aminolevulinic acid (ALA) (Warren, Cooper, Wood, and Shoolingin Jordan, 1998). Lead similarly inhibits ferrochelatase, the terminal enzyme that inserts iron into protoporphyrin IX to form heme. The resulting disruption of heme synthesis underlies lead-associated anemia and elevated erythrocyte protoporphyrin, while accumulated ALA itself is redox-active, auto-oxidizing to generate reactive oxygen species that contribute to oxidative stress in multiple tissues, including the central nervous system.

Ionic Mimicry of Calcium

Lead ions (Pb2+) closely mimic calcium ions in ionic radius and charge, allowing lead to compete for calcium binding sites on regulatory proteins including calmodulin and protein kinase C. This disrupts calcium-dependent signal transduction, including neurotransmitter release and synaptic plasticity, and is considered a principal mechanism underlying lead’s neurodevelopmental toxicity. The same calcium-mimicry mechanism allows lead to cross the blood-brain barrier and placenta via calcium transport systems that would otherwise exclude it.

Oxidative Stress

In addition to ALA-mediated radical generation, lead directly depletes cellular antioxidant defenses, including glutathione, and inhibits antioxidant enzymes, tipping cells toward a pro-oxidant state implicated in lead’s renal, cardiovascular, and neurological toxicity, as well as in the mechanistic basis proposed for its carcinogenicity (see Section 6).

Genotoxic and Epigenetic Mechanisms Relevant to Carcinogenicity

Lead is not believed to be a classical direct-acting mutagen; rather, its carcinogenic mechanism is generally attributed to indirect genotoxicity — oxidative DNA damage secondary to ALA-driven reactive oxygen species, inhibition of DNA repair enzymes, and interference with tumor-suppressor zinc-finger proteins by displacing structural zinc — together with epigenetic effects on gene expression. Consistent with an indirect mechanism, lead compounds have been shown to enhance viral-mediated cell transformation and adenovirus induction (Casto, Meyers, and DiPaolo, 1979) and to induce chromosomal aberrations, including sister chromatid exchange documented in occupationally exposed workers (Grandjean, Wulf, and Niebuhr, 1983).

4. Animal Toxicological Evidence by Organ System

Neurological / Neurodevelopmental

The neurodevelopmental effects of lead are the most extensively studied and most consistently replicated across species. Rice, Gilbert, and Willes (1979) orally dosed neonatal cynomolgus monkeys (Macaca fascicularis) with 500 µg/kg/day lead acetate beginning on day 1 of life; despite no overt clinical signs of toxicity, treated animals showed altered locomotor activity, disrupted schedule-controlled behavior, and abnormal responses to amphetamine challenge at 2–3 years of age, establishing that behaviorally significant neurotoxicity can occur at exposure levels producing no overt signs of poisoning. In rats, Cory-Slechta and Thompson (1979) demonstrated behavioral toxicity, including disrupted operant schedule-controlled responding, following chronic postweaning lead exposure, with subsequent work by Cory-Slechta and colleagues showing that the timing of exposure during development

RoseyFields — Chemical-Specific Toxicology Page: Lead

materially affects the behavioral outcome. Across species, comparative reviews have noted that the lowest exposure levels producing developmental neurobehavioral effects are broadly similar — roughly 10–15 µg/dL in children, below 15 µg/dL in nonhuman primates, and below 20 µg/dL in rodents — supporting cross-species concordance for this endpoint despite differences in absolute dose.

Renal

Goyer (1968) established the classic rat model of lead nephropathy, showing that lead exposure produces mitochondrial swelling and aminoaciduria in the proximal renal tubule. Khalil-Manesh, Gonick, Cohen, and colleagues (1992), in a comprehensive continuous high-dose model, administered 0.5% lead acetate in drinking water to male Sprague-Dawley rats for periods of 1 to 12 months; treated animals developed nephromegaly driven by proximal tubular hypertrophy, characteristic intranuclear lead inclusion bodies in proximal tubule nuclei, tubular atrophy and interstitial fibrosis emerging by six months, and focal glomerulosclerosis in a minority of animals by 12 months, alongside biphasic renal function changes — an early increase in glomerular filtration rate followed by a late decline. These findings define the classic dose- and duration-dependent progression of lead nephropathy used to interpret human renal biomarker and biopsy findings in lead-exposed populations.

Reproductive

Barratt, Davies, Bansal, and Williams (1989) administered lead acetate to male rats by gavage for 9 weeks at 0.3, 33, or 300 mg/kg/day; the lowest dose significantly reduced epididymal sperm counts, and the highest dose increased the proportion of morphologically abnormal sperm and reduced body weight gain, while testicular germ cell counts themselves were not significantly affected — an outcome the authors attributed to a partially protective blood-testis barrier. Other investigators have reported reduced serum testosterone, disrupted testicular steroidogenic enzyme activity, and impaired sperm motility and viability in lead-acetate-exposed rats, generally attributable in part to lead induced oxidative stress in testicular tissue. Effects on female reproduction and offspring viability have also been documented in rodent models, consistent with the developmental and reproductive effects noted qualitatively in the IRIS oral RfD discussion.

Cardiovascular

Victery, Vander, Shulak, Schoeps, and Julius (1982) demonstrated that chronic lead exposure elevates blood pressure in rats and implicated activation of the renin-angiotensin system as a contributing mechanism, a finding replicated and extended by subsequent studies documenting increased vascular reactivity to alpha-adrenergic agonists in lead-exposed rats. Reviews of this experimental literature have noted that lower-dose, longer-duration lead exposure protocols in rodents more consistently produce hypertension than very-high-dose, short-duration protocols, a dose-response pattern relevant to interpreting the epidemiological association between lead and blood pressure in humans.

Immune

McCabe and Lawrence (1991) showed that lead exerts differential, subset-specific immunomodulatory effects on CD4+ T-cell populations in mice, with subsequent work from the same group showing lead can both enhance certain B-cell responses (increased antibody-forming cell responses and MHC class II expression) and suppress others, indicating that lead’s immunotoxicity is not uniformly suppressive but reflects a shift in the balance of immune responses (Th1 versus Th2 skewing) rather than global immunosuppression. Reduced neutrophil phagocytic activity and altered complement receptor function on B lymphocytes have also been reported in lead-exposed animals.

Hepatic

RoseyFields — Chemical-Specific Toxicology Page: Lead

Hepatic effects of lead in animal studies are generally less pronounced than renal, neurological, or hematological effects at comparable exposure levels; reported findings include reduced hepatic protein synthesis at high dietary lead levels (as also noted incidentally in the Barratt et al. (1989) reproductive study, where the highest dose reduced hepatic lysine incorporation into protein) and lead-associated oxidative stress markers in liver tissue, but overt hepatocellular injury is not a prominent feature of lead toxicity relative to other organ systems.

Endocrine

Beyond the reproductive-hormonal effects noted above, lead has been shown in rat models to increase adrenal aldosterone production at blood lead levels comparable to those seen in exposed human populations, providing a candidate endocrine mechanism contributing to lead-associated hypertension distinct from the renin-angiotensin pathway.

Hematological

Consistent with the heme-synthesis mechanism described in Section 3, lead-exposed animals across species reliably show inhibited blood ALAD activity, elevated erythrocyte protoporphyrin, and, at sufficient dose and duration, frank anemia. This is among the most sensitive and best-quantified biochemical endpoints of lead toxicity in both animal models and occupationally exposed humans.

5. Animal Carcinogenicity Bioassay Findings

More than ten investigators have demonstrated the carcinogenic potential of soluble lead salts (chiefly acetates and phosphates) administered orally or by injection to rats and mice, with bilateral renal carcinoma as the most characteristic tumor response. Nearly all positive bioassays used soluble lead salts administered at or near the top of the tested dose range; metallic lead, lead oxide, and lead tetraalkyls have not been adequately tested for carcinogenicity, and inhalation carcinogenicity bioassays for lead have not been located in the published literature.

• Azar, Trochimowicz, and Maxfield (1973) fed lead acetate at dietary concentrations of 10, 50, 100, and 500 ppm to 50 rats/sex/group for two years (with a second study at 0, 1,000, and 2,000 ppm, 20 rats/group). No renal tumors occurred in controls or in animals receiving 10–100 ppm. Male rats developed renal tumor incidences of 5/50, 10/20, and 16/20 at 500, 1,000, and 2,000 ppm respectively, and 7/20 females developed renal tumors at 2,000 ppm.
• Kasprzak, Hoover, and Poirier (1985) fed 1% lead subacetate (8,500 ppm Pb) to male Sprague-Dawley rats for 79 weeks; of animals surviving beyond 58 weeks, 44.8% developed renal tumors (adenomas and adenocarcinomas), versus none in controls.
• Koller, Kerkvliet, and Exon (1986) administered lead acetate (2,600 ppm) in drinking water to male Sprague-Dawley rats for 76 weeks; 13 of 16 treated rats (81%) developed renal tubular carcinoma, versus none of 10 controls.
• Van Esch and Kroes (1969) fed basic lead acetate at 0, 0.1%, and 1.0% in the diet to Swiss mice for two years; 6 of 25 males at 0.1% developed renal tumors, with a lower incidence at 1.0% attributed to early mortality. Hamsters given lead subacetate at 0.5–1% showed no significant renal tumor response in the same study, illustrating species-dependent susceptibility.

Supporting mechanistic (genotoxicity-adjacent) evidence includes lead-acetate-induced cell transformation in Syrian hamster embryo cells (DiPaolo, Nelson, and Casto, 1978), enhanced viral transformation and adenovirus induction by lead acetate and lead oxide (Casto, Meyers, and DiPaolo, 1979), and increased sister chromatid exchange in lead exposed workers (Grandjean, Wulf, and Niebuhr, 1983) — consistent with the indirect, oxidative-stress-mediated genotoxic mechanism discussed in Section 3.

6. Animal Findings Compared with Human Epidemiological Evidence

RoseyFields — Chemical-Specific Toxicology Page: Lead

Neurodevelopmental Effects: Strong Concordance

Animal and human evidence align closely for neurodevelopmental toxicity. Early human cohort studies, including Needleman et al. (1979), linked elevated dentine lead levels to deficits in classroom performance and psychometric test scores in children with no history of clinical lead poisoning, a finding later extended by Canfield, Henderson, Cory-Slechta, Cox, Jusko, and Lanphear (2003), who documented intellectual impairment in children with blood lead concentrations below 10 µg/dL, and by Lanphear, Hornung, Khoury, Yolton, Baghurst, Bellinger, and colleagues (2005), whose international pooled analysis found no evidence of a threshold for lead’s effect on children’s intellectual function down to the lowest measured exposures. These findings are consistent with, and were substantially anticipated by, the primate work of Rice and colleagues and the rodent behavioral work of Cory Slechta and colleagues described in Section 4, which likewise found no clear no-effect exposure level. This concordance, combined with the absence of an identified threshold in either animal or human data, is the central scientific basis for EPA’s refusal to derive a numerical RfD for lead (see RoseyFields’ companion risk-assessment methodology page for lead).

Cardiovascular Effects: Concordant but with Effect-Size Uncertainty

Rodent studies (Victery et al., 1982, and subsequent work) reliably demonstrate lead-induced hypertension, and epidemiological studies have found associations between blood lead and blood pressure in adult populations, but the magnitude of the human association is smaller and less consistent across studies than the animal effect, and some human studies have found no significant relationship. Reviewers have attributed part of this divergence to the reliance in both species on blood lead as the exposure metric, despite blood lead’s short (about 30-day) half-life relative to the multi-year averaging period over which cardiovascular effects likely develop, meaning bone lead (reflecting cumulative, longer-term exposure) may be a more mechanistically appropriate but less commonly measured metric in human studies.

Carcinogenicity: Sufficient Animal Evidence, Inadequate Human Evidence

This is the clearest case of animal-human divergence for lead. As detailed in the IRIS carcinogenicity assessment, more than ten rat bioassays and one mouse bioassay show statistically significant, dose-related increases in renal tumors, whereas the four available human occupational cohort studies (Dingwall-Fordyce and Lane, 1963; Cooper and Gaffey, 1975; Cooper, 1985; Selevan, Landrigan, Stern, and Jones, 1985; Nelson, Kiremidjian-Schumacher, and Stotzky, 1982) show inconsistent, generally non-dose-responsive, and often non-statistically-significant excesses across different cancer sites, with no two studies identifying the same target organ. Plausible explanations for this divergence, beyond the possibility that the animal renal tumor response does not translate quantitatively to humans, include: (1) all human studies lacked quantitative individual exposure data, precluding dose-response analysis; (2) co-exposure to other metals (arsenic, cadmium, zinc) was uncontrolled in every study; (3) smoking, a major confounder for the specific cancer sites implicated (lung, stomach), was not addressed; and (4) the high doses required to produce tumors in rodents (generally at or near the maximum tolerated dose) may not be toxicokinetically comparable to real-world human exposure levels, particularly given the pharmacokinetic complications — skeletal body burden, non-linear absorption — that also preclude a quantitative animal-to-human cancer slope factor for this chemical.

Renal, Reproductive, and Hematological Effects: Concordant Direction, Limited Human Dose-Response Data

Human clinical and occupational studies of renal tubular dysfunction, male reproductive impairment (reduced sperm count and quality), and impaired hemoglobin synthesis in lead-exposed workers are qualitatively consistent with the animal findings summarized in Section 4, and the ALAD-inhibition mechanism underlying hematological effects has been directly demonstrated in both exposed workers and animal models. However, well-controlled human dose-

RoseyFields — Chemical-Specific Toxicology Page: Lead

response data adequate to establish a quantitative point of departure are limited by the same confounding and exposure-characterization problems noted for the cancer literature, reinforcing EPA’s conclusion that lead’s overall database, while extensive, does not support derivation of standard quantitative toxicity values.

7. Data Gaps and Areas of Ongoing Research

• Quantitative low-dose dose-response modeling: despite an extensive qualitative database, dose-response relationships at the very low blood lead levels now typical of the U.S. population (well below historical occupational and even historical childhood exposure levels) remain an active research area, particularly for neurodevelopmental and cardiovascular endpoints where no threshold has been identified.
• Cancer mechanism and human relevance: the extent to which the oxidative-stress/indirect-genotoxicity mechanism identified in rodent renal tumors operates quantitatively in humans, and whether the human epidemiological signal (concentrated in lung, stomach, and kidney in different studies) reflects a shared or distinct mechanism from the rodent renal tumor response, remains unresolved; a well-controlled, quantitatively exposure-characterized human cohort study, adjusted for smoking and co-exposure to other metals, does not yet exist.
• Bone lead as an exposure and effect biomarker: because blood lead reflects primarily recent exposure while bone lead reflects cumulative body burden, better integration of bone lead measurement (via K-shell x-ray fluorescence) into both animal and human dose-response studies is an ongoing methodological priority, particularly for endpoints (cardiovascular, cognitive decline in aging populations) thought to be driven by cumulative rather than recent exposure.
• Immunotoxicity dose-response and human health significance: animal data show lead can both enhance and suppress specific immune parameters depending on dose and the specific response measured, but the functional, health-relevant consequences of this dysregulation (e.g., altered susceptibility to infection, asthma, or autoimmunity) are not yet well quantified in either animal models or human populations.
• Genetic susceptibility: polymorphisms in the ALAD gene and other lead-handling genes have been associated with differences in blood lead level and, in some studies, susceptibility to specific lead associated effects; the practical significance of this variability for individual risk assessment remains an active area of study.
• Mixtures and co-exposure: because lead exposure in both historical occupational cohorts and many contemporary environmental settings co-occurs with other metals (arsenic, cadmium, zinc, manganese), interaction effects — antagonistic, additive, or synergistic — remain incompletely characterized for most of the organ systems discussed above.
• Updated ATSDR and IRIS review: EPA’s own screening-level literature reviews (2002) identified new studies relevant to lead’s noncancer effects but did not result in a revised RfD, and the ATSDR Toxicological Profile for Lead cited in the IRIS file dates to 1999; RoseyFields monitors both agencies, along with the peer-reviewed literature summarized above, for a future comprehensive reassessment.

Bibliography